Could ozempic help control diabetes in spinal cord injury patients?

NCT ID NCT06706284

Recruiting now Disease control Sponsor: Marzieh Salehi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether semaglutide (Ozempic), a drug used for type 2 diabetes, works well for people with spinal cord injury (SCI) who also have diabetes. SCI patients are at higher risk for diabetes, but it's unclear if standard treatments are effective. The trial will measure blood sugar control and weight loss in 50 adults with SCI and type 2 diabetes, comparing semaglutide to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (Ozempic)
What this could lead to: If it works, this could provide an effective diabetes treatment option tailored for people with spinal cord injury, who are at higher risk for type 2 diabetes.
What could go wrong: This is a small Phase 4 trial with only 50 participants, so results may not apply to everyone. Semaglutide can cause side effects like nausea and vomiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL CORD INJURIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

spinal cord injury type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SPINAL CORD INJURIES TYPE 2 DIABETES

Contacts and locations

Locations

University Health - Texas Diabetic Institute
RECRUITING

San Antonio, Texas, 78207, United States
University of Texas Health Science Center at San Antonio
RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.